Recurrent Acute Rhinosinusitis

Bhattacharyya, Neil; Grebner, Jeff; Martinson, Noel G.

doi:10.1177/0194599811426089

Cited by 70 publications

(17 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results are similar to those from a retrospective cohort study from Brazil, which found that ART comprising three antiretrovirals was associated with a significantly lower prevalence of otorrhea (7.1%) than children receiving only one or two antiretrovirals (20.8%) (p = 0.02) [7]. The mean age in this study was 6.6 (± 2.5) years, far older than in our study.…”

Section: Discussionsupporting

confidence: 89%

See 1 more Smart Citation

Early Antiretroviral Therapy reduces the incidence of otorrhea in a randomized study of early and deferred antiretroviral therapy: Evidence from the C hildren with H IV E arly Antir etroviral Therapy (CHER) Study

et al. 2011

View full text Add to dashboard Cite

BackgroundAlthough otorrhea occurs commonly in HIV-infected infants, there are few data. We compared the incidence of otorrhea in infants receiving early vs deferred ART in the Children with HIV Early Antiretroviral (CHER) trial. Infants aged 6 to 12 weeks of age with confirmed HIV infection and a CD4 percentage greater than or equal to 25% were randomized to early or deferred ART at two sites in South Africa. Medical records from one study site were reviewed for otorrhea.FindingsData were reviewed from the start of the trial in July 2005 until 20 June 2007, when the Data Safety Monitoring Board recommended that randomization to the deferred arm should stop and that all infants in this arm be reviewed for commencing antiretroviral therapy. Infants entered the study at a median of 7.4 weeks of age. Eleven of 38 (29%) on deferred therapy and 7 of 75 (9%) in the early-therapy group developed otorrhea (risk ratio 3.1, 95% confidence interval (CI) 1.31-7.36; p = 0.01).ConclusionsEarly initiation of antiretroviral therapy is associated with significantly less otorrhea than when a deferred strategy is followed.Trial registrationNCT00102960. ClinicalTrials.Gov

show abstract

Section: Discussionsupporting

confidence: 89%

“…Both occur frequently in HIV-infected children [4-6]. Antiretroviral therapy (ART) was associated with a reduction in otitis media and CSOM in a retrospective cohort [7]. …”

Section: Introductionmentioning

confidence: 99%

Early Antiretroviral Therapy reduces the incidence of otorrhea in a randomized study of early and deferred antiretroviral therapy: Evidence from the C hildren with H IV E arly Antir etroviral Therapy (CHER) Study

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Acute rhinosinusitis is an important health problem that seriously affects the quality of life of sufferers, and represents a considerable economic burden for society [ 1 , 2 ]. Although many studies on the mechanisms of acute rhinosinusitis have been carried out, they are not yet clearly understood.…”

Section: Introductionmentioning

confidence: 99%

NLRP3 Inflammasome Sequential Changes in Staphylococcus aureus-Induced Mouse Model of Acute Rhinosinusitis

Wang

Gong

Chen

et al. 2014

IJMS

View full text Add to dashboard Cite

The NLR pyrin domain containing 3 (NLRP3) inflammasome plays a crucial role in lung disease and may have a similar role in upper respiratory tract inflammation. We therefore constructed a C57BL/6 mouse model of acute rhinosinusitis induced by Staphylococcus aureus and investigated the role of the NLRP3 inflammasome in this model. Mice were classified as non-inoculated group (group A) and inoculated groups (groups B, C, D and E, sacrificed 1, 3, 7 and 14 days after inoculation, respectively). Hematoxylin-eosin staining showed that each group had inflammatory cell infiltration, except group A. The damage of the nasal mucosa was aggravated gradually over time. Western blot and immunofluorescence showed that the structural proteins of the NLRP3 inflammasome (NLRP3, ASC (apoptosis-associated speck-like protein containing CARD), procaspase-1) in groups B, C, D and E were increased gradually. But they were reduced in group B compared with group A, except for NLRP3. Western blot showed that the cleavage fragment of procaspase-1, p20 in groups B, C, D and E was increased gradually. Real-time PCR showed that the corresponding mRNAs of the structural proteins were changed the same as their proteins. IL-1β mRNA and mature IL-1β protein were increased gradually in groups A, B, C, D and E. These results indicate that NLRP3 inflammasome activation was associated with the acute rhinosinusitis, and that there was a positive correlation between the expression level of the NLRP3 inflammasome and the severity of acute rhinosinusitis.

show abstract

“…1 The aggregated cost of rhinosinusitis is approximately 8.6 billion dollars annually, and the disease affects an estimated 16% of the population in the United States. 1, 2 In addition to the financial burden on the health system, quality of life and health utility studies have shown significant morbidity associated with rhinosinusitis, comparable to that of other chronic illnesses such as congestive heart failure and chronic obstructive pulmonary disease (COPD). 3, 4 The loss of the sense of smell, which often accompanies chronic rhinosinusitis (CRS), further compromises quality of life.…”

mentioning

confidence: 99%

Correlation of T2R38 taste phenotype and in vitro biofilm formation from nonpolypoid chronic rhinosinusitis patients

Adappa

Truesdale

Workman

et al. 2016

Int Forum Allergy Rhinol

View full text Add to dashboard Cite

Background Sinonasal biofilms have been demonstrated in specimens collected from chronic rhinosinusitis (CRS) patients. Mounting evidence suggests that biofilms contribute to therapeutically recalcitrant CRS. Recently, the bitter taste receptor T2R38 has been implicated in the regulation of the sinonasal mucosal innate immune response. TAS2R38 gene polymorphisms affect receptor functionality and contribute to variations seen in sinonasal innate defense as well as taste perception reflected in gustatory sensitivity to the bitter compound phenylthiocarbamide (PTC). In a population of CRS patients with active infection or inflammation, we sought to determine if a correlation between T2R38 phenotype and in vitro biofilm formation existed. Methods Endoscopically guided sinonasal swabs were obtained prospectively from CRS (±polyp) patients with evidence of persistent inflammation or mucopurulence. In vitro biofilm formation was assessed with a modified Calgary Biofilm Detection Assay. Patients' phenotypic (functional) expression of the bitter taste receptor T2R38 was evaluated with a taste test including the compound PTC. Linear regression was used to determine the level of significance between mean in vitro biofilm formation levels and mean PTC taste test intensity ratings across CRS patients. Results Sinonasal swabs were obtained from 59 patients, with 42 of the 59 samples demonstrating in vitro biofilm formation. Analysis revealed an inverse linear association between in vitro biofilm formation and PTC taste intensity ratings (p = 0.019) for all patients. This association was exclusively driven by nonpolypoid CRS patients (p = 0.0026). Conclusion In vitro biofilm formation from sinonasal clinical isolates is inversely correlated with PTC taste sensitivity in nonpolypoid CRS patients.

show abstract

Recurrent Acute Rhinosinusitis

Cited by 70 publications

References 12 publications

Early Antiretroviral Therapy reduces the incidence of otorrhea in a randomized study of early and deferred antiretroviral therapy: Evidence from the C hildren with H IV E arly Antir etroviral Therapy (CHER) Study

Early Antiretroviral Therapy reduces the incidence of otorrhea in a randomized study of early and deferred antiretroviral therapy: Evidence from the C hildren with H IV E arly Antir etroviral Therapy (CHER) Study

NLRP3 Inflammasome Sequential Changes in Staphylococcus aureus-Induced Mouse Model of Acute Rhinosinusitis

Correlation of T2R38 taste phenotype and in vitro biofilm formation from nonpolypoid chronic rhinosinusitis patients

Contact Info

Product

Resources

About